Physcion-d3

Physcion-d3 (Parietin-d3) is the deuterium labeled Physcion. Physcion acts as an inhibitor of 6-phosphogluconate dehydrogenase, with an IC50 and a Kd of 38.5 μM and 26.0 μM, respectively. Physcion exhibits laxative, hepatoprotective, anti-inflammatory, anti-microbial, anti-proliferative and anti-tumor effects[1][2][3].

Product Specifications

CAS Number

1215751-27-1

Product Name Alternative

Parietin-d3; Rheochrysidin-d3

UNSPSC

12352005

Target

Bacterial; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Anti-infection; Others

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Infection; Inflammation/Immunology

Purity

99.82

Solubility

DMF : 1mg/mL (ultrasonic) |DMSO : 3.33mg/mL (ultrasonic; warming; adjust pH to 9 with NaOH; heat to 60°C) |THF : 2.5mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1C2=CC(OC([2H])([2H])[2H])=CC(O)=C2C(C3=C(O)C=C(C)C=C31)=O

Molecular Formula

C16H9D3O5

Molecular Weight

287.28

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Lin R, et al. 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. Nat Cell Biol. 2015 Nov;17 (11) :1484-96.|[3]Pang MJ, et al. Physcion, a naturally occurring anthraquinone derivative, induces apoptosis and autophagy in human nasopharyngeal carcinoma. Acta Pharmacol Sin. 2016 Dec;37 (12) :1623-1640.